Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Q3 Revenue Up 10 Percent on Increased LAS Business

NEW YORK, Oct. 29 (GenomeWeb News) - PerkinElmer said today that increasing revenues in its Life and Analytical Sciences division offset lower biopharma receipts and helped the company post a 10-percent jump in third-quarter revenue.

Total receipts for the period ended Sept. 30 increased to $403 million from $366 million one year ago. Revenue from the company's Life and Analytical Sciences division, which offers products for genetic screening, service, and environment, grew 4 percent, to $243.7 million from $235.1 million.

 

PerkinElmer's life and analytical sciences business reported revenues of $244 million for the period, up from $235 million for the third quarter in 2003.


Research and development expenses were $21 million for the period, up from $20 million for the same quarter in 2003.

 

Net income during the quarter surged to $24 million, or $. 19 per share, from $14 million, or $.11 per share, in the year-ago quarter.

 

The company reported cash and cash equivalents of $220 million on hand at the end of the quarter.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.